Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Fatima Talab"'
Autor:
Nagesh Kalakonda, Lynn Cawkwell, Kathleen J. Till, Andrew R. Pettitt, Fatima Talab, David Allsup, Joseph R. Slupsky, Ingo Ringshausen, Alison Bentley, John C. Allen, Andrew D. Duckworth, Ke Lin
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
SCIENTIFIC REPORTS
Scientific Reports
SCIENTIFIC REPORTS
Scientific Reports
Pathogenesis of chronic lymphocytic leukaemia (CLL) is contingent upon antigen receptor (BCR) expressed by malignant cells of this disease. Studies on somatic hypermutation of the antigen binding region, receptor expression levels and signal capacity
Autor:
Helen Mason, Simon Scrace, Richard Testar, Julie Rainard, Fatima Talab, Ryaka Poonawala, Philippa Smith, Harriet Brooke, Sarah Frith, Jonathan Ahmet, Jonathan Hall, David Sorrell, Jon Moore, Caroline Phillips, Dennis France, Matilda Bingham, Richard Armer
Publikováno v:
Cancer Research. 77:5160-5160
REDX05358 has been identified as a novel, highly selective and potent next generation pan RAF inhibitor with improved therapeutic potential and predicted safety profile. Aberrant signalling via the MAPK pathway is commonly seen in cancer. RAF inhibit
Autor:
Matilda Bingham, Rose Mantel, Fatima Talab, Peggy Cousin, Caroline Phillips, Nicolas E. S. Guisot, Valentina Abet, Andrew Thomason, Richard Armer, Melanie Muller, Julienne Refuerzo, Juliette Emmerich, Kelvin Ho, Stuart A. Best, James King-Tours, Kristina Lyons, Louise Sargent, Fabienne McClanahan, Diana Castagna, Victoria Wright, Jennifer A. Woyach, James Kelly
Publikováno v:
Blood. 128:4399-4399
Here we report the preclinical profile of REDX08608 our novel, potent and selective, reversible BTK inhibitor that is equipotent against wild-type and mutant C481S BTK. Bruton's tyrosine kinase (BTK) is a member of the src-related Tec family of cytop
Publikováno v:
Molecular cancer research : MCR. 11(5)
B-cell receptor (BCR) signals promote survival of chronic lymphocytic leukemia (CLL) cells, and it is believed that overexpressed and constitutively active Lyn mediates this signaling. Here, we show that CLL cells express lymphocyte-specific protein
Autor:
Rose Chappell, Victoria Walker, Caroline Phillips, Madelene Waldron, Valentina Abet, Nicolas E. S. Guisot, Melanie Müller, Julienne Refuerzo, Kelvin Ho, Matilda Bingham, Stuart A. Best, Mary-Ann Campbell, Fatima Talab, Juliette Emmerich, James Kelly, Kristina Lyons, Richard Armer, Louise Sargent
Publikováno v:
Cancer Research. 76:4795-4795
Redx Oncology has developed novel, differentiated, reversible small molecule inhibitors of BTK, combining current best-in-class potency with improved selectivity profiles, which are suitable for oral, once daily dosing, designed to be equipotent agai
Autor:
Juliette Emmerich, Matilda Bingham, Stuart A. Best, Richard Armer, Julienne Refuerzo, Nicolas E. S. Guisot, Melanie Muller, Victoria Walker, Fatima Talab, Rose Chappell, Mary-Ann Campbell, Shona Harmon, Kelvin Ho, Lauren Proctor, Mathew Calder, Catherine Lucas
Publikováno v:
Blood. 126:4848-4848
The B-cell receptor (BCR) signaling pathway is required for the survival, activation, proliferation and differentiation of B-cells. Bruton's Tyrosine Kinase (BTK) is a member of the Tec protein tyrosine kinase family that has emerged as an attractive
Publikováno v:
Blood. 117(8)
Chronic lymphocytic leukemia (CLL) is a malignancy characterized by clonal expansion of mature B cells that are resistant to apoptosis. This resistance to apoptosis partly results from Mcl-1 expression because high levels of this protein in CLL cells
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 11:S162
Publikováno v:
Blood. 116:375-375
Abstract 375 B cell receptor (BCR) signaling promotes survival of the malignant clone in chronic lymphocytic leukaemia (CLL) through its ability to stimulate NFkB pathway signaling. In lymphoid cells, antigen receptor stimulation of this pathway is a